The obscure advisory committees at the heart of the U.S. drug pricing debate
By Caroline HumerCHICAGO, April 29 (Reuters) - Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly...
By Caroline HumerCHICAGO, April 29 (Reuters) - Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly...